Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Artiva Biotherapeutics, Inc. (ARTV) is a Biotechnology company based in US with a market capitalization of $193.8M. Free cash flow was negative at -$79.3M. This page tracks ARTV's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 96 employees · IPO Jul 19, 2024

Valuation

Valuation & price

$9.78as of May 17, 2026· -27.0% vs 52w high

P/E ratio

Latest-FY diluted EPS

1.76

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$13.39$7.49$1.58Jul 25Dec 25Jun 26
$1.5852-week range$13.39
Loading valuation history…

Fundamentals

Key fundamentals

$193.8M

Market cap

Revenue growth (YoY)

100.0%

Gross margin

-$79.3M

Free cash flow (USD)

-$97.1M

Net debt

Net cash position

0.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20202025

$0$0

Free cash flow by year

20202025

-$13.8M-$79.3M

Gross margin by year

20212024

100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

5

Insider buys · 90 days

5

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider buyJun 29, 2026Filing

    Insider Buy $292KRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $292.1K

  • Insider buyJun 16, 2026Filing

    Insider Buy $4.6MRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $4.6M

  • Insider buyJun 11, 2026Filing

    Insider Buy $7.7MRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $7.7M

  • Insider buyMay 28, 2026Filing

    Insider Buy $16.5MGC Corp. · 10% Owner · $16.5M

  • Insider sellMay 19, 2026Filing

    Insider Sell $244KAslan Fred · Director, Chief Executive Officer · $244.3K

  • Insider sellMay 19, 2026Filing

    Insider Sell $63KBanerjee Subhashis · Chief Medical Officer · $63.4K

  • Insider sellMay 19, 2026Filing

    Insider Sell $79KBush Jennifer · COO, CLO, Compliance Officer · $79.2K

  • Insider sellMay 19, 2026Filing

    Insider Sell $63KHoran Christopher · Chief Tech Operations Officer · $63.1K

  • Insider sellMay 19, 2026Filing

    Insider Sell $28KRaymon Heather · SVP, Research and Development · $27.9K

  • 8-K eventMay 19, 2026Filing

    Executive Departures and Appointments

Questions

Frequently asked questions

What is Artiva Biotherapeutics, Inc.'s market cap?

Artiva Biotherapeutics, Inc. (ARTV) has a market capitalization of $193.8M.

What is ARTV's P/E ratio?

A meaningful P/E ratio is not available for ARTV — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ARTV's price-to-book (P/B) ratio?

ARTV trades at 1.76 times book value per share.

Are insiders buying ARTV stock?

Yes — SEC Form 4 filings show 5 open-market insider buys and 5 sells at Artiva Biotherapeutics, Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.